Protection against canine parvovirus type 2 infection in puppies by colostrum-derived antibodies
- PMID: 26101622
- PMCID: PMC4473144
- DOI: 10.1017/jns.2014.57
Protection against canine parvovirus type 2 infection in puppies by colostrum-derived antibodies
Abstract
During the first weeks of life puppies remain protected against canine parvovirus type 2 (CPV2) infection thanks to maternally derived antibodies (MDA) absorbed with colostrum after birth. The objective of the present study was to present the variability in CPV2-specific passive immune transfer and its consequences in puppies naturally exposed to the parvovirus. Seventy-nine puppies from one breeding kennel were included in the study at birth and followed until 56 d of age. Once per week the MDA titre for CPV2 specific antibodies was determined in blood. Viral excretion was also evaluated on a rectal swab by CPV2 PCR assay and puppies were weighed to determine growth rate. At 2 d of age, thirty-four out of seventy-nine puppies (43 %) had MDA ≤1:160 (designed group A) and forty-five puppies (57 %) had greater MDA titres (designed group B). The level of absorbed maternal antibodies was shown to be associated with breed size and growth rate during the first 48 h of life. The MDA level declined with age in all cases; however, the proportion of puppies with the antibody level considered as protective against CPV2 infection was significantly higher in group B compared with A from day 2 until 42. Among all puppies surviving until 56 d of age, sixty-seven out of seventy (95·7 %) underwent CPV2 infection. However, puppies from group A excreted CPV2 significantly earlier than puppies from group B. The present study demonstrates the link between passive immune transfer, in terms of level of specific MDA absorbed, and length of the protection period against parvovirus infection in weaning puppies.
Keywords: CPV2, canine parvovirus type 2; Canine parvovirus; Colostrum; HI, haemagglutination inhibition; MDA, maternally derived antibodies; Maternally derived antibodies; Puppies.
Figures
Similar articles
-
General and type 2 parvovirus-specific passive immune transfer in puppies - Evaluation by early growth.Reprod Domest Anim. 2018 Nov;53 Suppl 3:96-102. doi: 10.1111/rda.13334. Reprod Domest Anim. 2018. PMID: 30474332
-
Discrepancy Between In-clinic and Haemagglutination-Inhibition Tests in Detecting Maternally-Derived Antibodies Against Canine Parvovirus in Puppies.Front Vet Sci. 2021 Mar 1;8:630809. doi: 10.3389/fvets.2021.630809. eCollection 2021. Front Vet Sci. 2021. PMID: 33732742 Free PMC article.
-
Inadequate passive immune transfer in puppies: definition, risk factors and prevention in a large multi-breed kennel.Prev Vet Med. 2014 Sep 1;116(1-2):209-13. doi: 10.1016/j.prevetmed.2014.05.001. Epub 2014 May 17. Prev Vet Med. 2014. PMID: 24880625
-
Natural and artificial hyperimmune solutions: Impact on health in puppies.Reprod Domest Anim. 2017 Apr;52 Suppl 2(Suppl 2):163-169. doi: 10.1111/rda.12824. Epub 2016 Nov 15. Reprod Domest Anim. 2017. PMID: 27862411 Free PMC article. Review.
-
Development of Dog Immune System: From in Uterus to Elderly.Vet Sci. 2019 Oct 21;6(4):83. doi: 10.3390/vetsci6040083. Vet Sci. 2019. PMID: 31640234 Free PMC article. Review.
Cited by
-
Update on Canine Parvoviral Enteritis.Vet Clin North Am Small Anim Pract. 2020 Nov;50(6):1307-1325. doi: 10.1016/j.cvsm.2020.07.008. Epub 2020 Sep 2. Vet Clin North Am Small Anim Pract. 2020. PMID: 32891439 Free PMC article. Review.
-
Comparative immune responses of pups following modified live virus vaccinations against canine parvovirus.Vet World. 2019 Sep;12(9):1422-1427. doi: 10.14202/vetworld.2019.1422-1427. Vet World. 2019. PMID: 31749576 Free PMC article.
-
Incidence and Predictors of Canine Parvovirus Diagnoses in Puppies Relocated for Adoption.Animals (Basel). 2021 Apr 9;11(4):1064. doi: 10.3390/ani11041064. Animals (Basel). 2021. PMID: 33918569 Free PMC article.
-
The first evaluation of the effectiveness of canine vaccination schedule by two commercial vaccines in Iran.BMC Vet Res. 2022 Mar 29;18(1):119. doi: 10.1186/s12917-022-03219-2. BMC Vet Res. 2022. PMID: 35351134 Free PMC article.
-
Development of a Novel Canine Parvovirus Vaccine Capable of Stimulating Protective Immunity in Four-Week-Old Puppies in the Face of High Levels of Maternal Antibodies.Vaccines (Basel). 2023 Sep 18;11(9):1499. doi: 10.3390/vaccines11091499. Vaccines (Basel). 2023. PMID: 37766175 Free PMC article.
References
-
- Decaro N, Desario C, Amorisco F, et al. (1997) Detection of a canine parvovirus type 2c with a non-coding mutation and its implications for molecular characterisation. Vet J Lond Engl 196, 555–557. - PubMed
-
- Glickman LT, Domanski LM, Patronek GJ, et al. (1985) Breed-related risk factors for canine parvovirus enteritis. J Am Vet Med Assoc 187, 589–594. - PubMed
-
- Pollock RV & Carmichael LE (1982) Maternally derived immunity to canine parvovirus infection: transfer, decline, and interference with vaccination. J Am Vet Med Assoc 180, 37–42. - PubMed
-
- Gooding GE & Robinson WF (1982) Maternal antibody, vaccination and reproductive failure in dogs with parvovirus infection. Aust Vet J 59, 170–174. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources